Stephen E. Fawell

12.6k citations

64 papers · 5.0k indexed · 3 hit papers · h-index 30

Impact in

Genetics top 0.5%
- Estrogen and related hormone effects
- Virus-based gene therapy research
Molecular Biology top 2%
- RNA Interference and Gene Delivery
- Advanced biosensing and bioanalysis techniques
- Retinoids in leukemia and cellular processes
- Protein Degradation and Inhibitors

Papers in

Toxicology 6
- Bioactive Compounds and Antitumor Agents 6
Genetics 18
- Estrogen and related hormone effects 12
- Virus-based gene therapy research 5

Co-authors: Malcolm G. Parker James Barsoum Blake Pepinsky J Seery Carol Moore Jacqueline A. Lees R White Susan Hoare
Journals: Cancer Research (12 papers)Molecular and Cellular Endocrinology (5 papers)Blood (4 papers)Oncotarget (3 papers)Proceedings of the National Academy of Sciences (3 papers)
Partner nations: United States United Kingdom Australia

In The Last Decade

Stephen E. Fawell

63 papers receiving 4.9k citations

Hit Papers

align trajectories log scale

Challenges and Opportunities in Cancer Drug Resistance 2020 · 330 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2020 Chemical Reviews
1994 Proceedings of the National Academy of Sciences
1990 Cell

Peers

Countries citing papers authored by Stephen E. Fawell

Since Specialization

Citations

This map shows the geographic impact of Stephen E. Fawell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen E. Fawell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen E. Fawell more than expected).

Fields of papers citing papers by Stephen E. Fawell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen E. Fawell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen E. Fawell. The network helps show where Stephen E. Fawell may publish in the future.

Co-authors

The 25 scholars most cited alongside Stephen E. Fawell, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Stephen E. Fawell Line = papers co-authored together Stephen E. Fawell links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	146 (PB134): First disclosure of AZD3470, a highly potent MTA-cooperative PRMT5 inhibitor in PRIMROSE and PRIMAVERA clinical studies European Journal of Cancer ·Julian R. Smith, Jelena Urosevic, S. Breanndan Moore, Łukasz Magiera, Lisa Bradshaw, Davide Gianni, Bharath Srinivasan, J.E. Debreczeni, C. W. Stubbs, Mercedes Vázquez–Chantada, Tao Hong, Anna Cronin, Karim Khan, Eve J. Wiseman, Douglas Ferguson, James T. Lynch, Hing Man Chan, S. Critchlow, Stephen E. Fawell, Emma Dean	2024	0
2	Abstract 3453: First disclosure of a highly potent and selective HPK1 inhibitor that rescues T cell exhaustion Cancer Research ·Deanna A. Mele, Neil P. Grimster, Gayathri Bommakanti, Jason Shields, Lucas A. Morrill, Kathryn Giblin, Maryann SanMartin, Yanjun Wang, Minwei Ye, Iswarya KarapaReddy, Kun Song, Theresa A. Proia, Niresh Hariparsad, Ryan M. Richards, Nadia Luheshi, Simon T. Barry, Stephen E. Fawell	2023	3
3	Macrophage Activation Status Rather than Repolarization Is Associated with Enhanced Checkpoint Activity in Combination with PI3Kγ Inhibition Molecular Cancer Therapeutics ·Larissa S. Carnevalli, Molly A. Taylor, Matthew King, Anna Coenen-Stass, Adina Hughes, Sigourney Bell, Theresa A. Proia, Yanjun Wang, Antonio Ramos‐Montoya, Neha Wali, Danielle Carroll, Maneesh Singh, Michele Moschetta, Pablo Morentin Gutierrez, Cristina Gardelli, Susan E. Critchlow, Teresa Klinowska, Stephen E. Fawell, Simon T. Barry	2021	14
4	BRD4 facilitates replication stress-induced DNA damage response Oncogene ·Jingwen Zhang, Austin Dulak, Maureen M. Hattersley, Brandon S. Willis, Jenni Nikkilä, Anderson T. Wang, Alan Lau, Corinne Reimer, Michael Zinda, Stephen E. Fawell, Gordon B. Mills, Huawei Chen	2018	67
5	Dissecting Therapeutic Resistance to ERK Inhibition Molecular Cancer Therapeutics ·Sharda Jha, Erick J. Morris, Alan Hruza, My Sam Mansueto, Gottfried K. Schroeder, Jaren Arbanas, Daniel R. McMasters, Clifford R. Restaino, Priya Dayananth, Stuart Black, Nathaniel L. Elsen, Anthony Mannarino, Alan Cooper, Stephen E. Fawell, Leigh Zawel, Lata Jayaraman, Ahmed A. Samatar	2016	39
6	The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient–Derived Xenograft Models Clinical Cancer Research ·Alwin G. Schuller, Evan Barry, Rhys D.O. Jones, Ryan E. Henry, Melanie M. Frigault, Garry Beran, David Linsenmayer, Maureen M. Hattersley, Aaron Smith, Joanne Wilson, Stefano Cairo, Olivier Déas, Delphine Nicolle, Ammar Adam, Michael Zinda, Corinne Reimer, Stephen E. Fawell, Edwin Clark, Celina M. D’Cruz	2015	57
7	Preclinical Evaluation of the WEE1 Inhibitor MK-1775 as Single-Agent Anticancer Therapy Molecular Cancer Therapeutics ·Amy D. Guertin, Jing Li, Yaping Liu, Melissa S. Hurd, Alwin G. Schuller, Brian J. Long, Heather A. Hirsch, Igor Feldman, Yair Benita, Carlo Toniatti, Leigh Zawel, Stephen E. Fawell, D. Gary Gilliland, Stuart D. Shumway	2013	143
8	Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T‐cell lymphoma models: Defining molecular mechanisms of resistance International Journal of Cancer ·Wenlin Shao, Joseph D. Growney, Yun Feng, Gregory O’Connor, Minying Pu, Wenjing Zhu, Yung‐Mae Yao, Paul Kwon, Stephen E. Fawell, Peter Atadja	2010	77
9	Potent anticancer activity of the pan-deacetylase inhibitor panobinostat (LBH589) as a single agent in in vitro and in vivo tumor models Cancer Research ·Wenlin Shao, Joseph D. Growney, Yun Feng, Ping Wang, Yan Yan‐Neale, Gregory O’Connor, Paul Kwon, Yung‐Mae Yao, Stephen E. Fawell, Peter Atadja	2008	15
10	Potent anticancer activity of the deacetylase inhibitor panobinostat (LBH589) in colon cancer cell lines and patient-derived primary colon cancer xenografts Cancer Research ·Youzhen Wang, Joseph D. Growney, Jane Cheng, Colleen Kowal, Guizhi Yang, Rebecca Mosher, Ronald A. Meyer, Yan Yan‐Neale, Minying Pu, Wenlin Shao, Yun Feng, Paul Kwon, Peter Atadja, Stephen E. Fawell, Yung‐Mae Yao	2008	2
11	A Smac Mimetic Rescue Screen Reveals Roles for Inhibitor of Apoptosis Proteins in Tumor Necrosis Factor-α Signaling Cancer Research ·Alex Gaither, Dale Porter, Yao Yao, Jason Borawski, Guang Yang, Jerry Donovan, David R. Sage, Joanna Slisz, Mary Tran, Christopher Straub, Tim Ramsey, Vadim Iourgenko, Alan Huang, Yan Chen, Robert Schlegel, Mark Labow, Stephen E. Fawell, William R. Sellers, Leigh Zawel	2007	178
12	Identification of SFRP1 as a Candidate Mediator of Stromal-to-Epithelial Signaling in Prostate Cancer Cancer Research ·Margaret S. Joesting, Steve Perrin, Brian Elenbaas, Stephen E. Fawell, Jeffrey S. Rubin, Omar E. Franco, Simon W. Hayward, Gerald R. Cunha, Paul C. Marker	2005	129
13	Fibronectin Type III Repeats Mediate RGD-independent Adhesion and Signaling through Activated β1 Integrins Journal of Biological Chemistry ·G Chi-Rosso, Philip J. Gotwals, Jianliang Yang, Leona Ling, Kate Jiang, B H Chao, Darren P. Baker, Linda C. Burkly, Stephen E. Fawell, Victor Koteliansky	1997	56
14	The alpha1beta1 integrin is expressed during neointima formation in rat arteries and mediates collagen matrix reorganization. Journal of Clinical Investigation ·Philip J. Gotwals, G Chi-Rosso, Volkhard Lindner, J. Yang, Lei Ling, Stephen E. Fawell, V.E. Koteliansky	1996	104
15	Generation of a Potent Chimeric Toxin by Replacement of Domain III of Pseudomonas Exotoxin with Ricin A Chain-KDEL Bioconjugate Chemistry ·Carol Pitcher, Lynne M. Roberts, Stephen E. Fawell, Alex G. Zdanovsky, David J. FitzGerald, Jonathan Lord	1995	5
16	Analysis of oestrogen receptor dimerisation using chimeric proteins The Journal of Steroid Biochemistry and Molecular Biology ·R White, Stephen E. Fawell, Malcolm G. Parker	1991	16
17	A Proposed Consensus Steroid-Binding Sequence—a Reply Molecular Endocrinology ·Stephen E. Fawell, Jacqueline A. Lees, Malcolm G. Parker	1989	33
18	Identification of two transactlvation domains in the mouse oestrogen receptor Nucleic Acids Research ·Jacqueline A. Lees, Stephen E. Fawell, Malcolm G. Parker	1989	254
19	Stimulation by Mammalian Insulin of Glycogen Metabolism in a Wall-Less Strain of Neurospora crassa* Endocrinology ·Stephen E. Fawell, M A McKenzie, Norma J. Greenfield, Foluso Adebodun, Frank Jordan, John Lenard	1988	19
20	A specific insulin receptor and tyrosine kinase activity in the membranes of Neurospora crassa Biochemical and Biophysical Research Communications ·Stephen E. Fawell, John Lenard	1988	26

About Stephen E. Fawell

Stephen E. Fawell is a scholar working on Toxicology, Genetics, Molecular Biology, Oncology and Immunology and Allergy, having authored 64 papers that have together received 5.0k indexed citations. Recurring topics across this work include Estrogen and related hormone effects (12 papers), Histone Deacetylase Inhibitors Research (9 papers), Protein Degradation and Inhibitors (8 papers), Bioactive Compounds and Antitumor Agents (6 papers), Virus-based gene therapy research (5 papers), Cancer Immunotherapy and Biomarkers (4 papers), Cancer Mechanisms and Therapy (4 papers) and RNA Interference and Gene Delivery (4 papers). The work is most often cited by research in Genetics (2.0k citations), Molecular Biology (3.4k citations), Oncology (1.0k citations), Immunology and Allergy (201 citations) and Immunology (632 citations). Stephen E. Fawell has collaborated with scholars based in United States, United Kingdom and Australia. Frequent co-authors include Malcolm G. Parker, James Barsoum, Blake Pepinsky, J Seery, Carol Moore, Jacqueline A. Lees, R White, Susan Hoare, Stephen J. Higgins and Mark Sydenham. Their work appears in journals such as Cancer Research, Molecular and Cellular Endocrinology, Blood, Oncotarget and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact